Topic:

Influenza

Latest Headlines

Latest Headlines

After rocky flu season, vaccinemakers may want to follow Novartis' lead

Heading into this year's flu season, vaccinemakers were hoping to follow up the top-line success they scored last year with quadrivalent rollouts. But with this year's vaccines registering a paltry 23% effectiveness rate this season thanks to a mutated strain, it might be time to make some changes.

Back from the scrap heap, BioCryst wins OK for IV flu drug

BioCryst Pharmaceuticals won its first-ever FDA approval for a new treatment and subsequently saw its shares slide as analysts yawned over its sales potential.

Sanofi adds another quadrivalent to its quiver with Fluzone Intradermal approval

Last year, Sanofi's fourth-quarter flu vaccine sales soared on the introduction of a quadrivalent contender, surging more than 94%. Now, looking to keep that growth coming, the company is adding another four-strain shot to the mix.

UPDATED: Novartis' Fluad off the hook in Italy following 19 deaths

After last week partially banning Novartis' Fluad, Italian officials now say tests on the flu vaccine show the product is safe.

Could oral vaccines shake up the flu shot market? Vaxart's Ph I says maybe

Flu shots are a driving sales force for more than a couple vaccine players. But could an oral alternative disrupt the flu vaccine market down the line?

Novartis drafts TV celeb Nick Cannon to talk up importance of flu vaccines

To help show Americans just how important its flu vaccines are, Novartis has teamed up with entertainer Nick Cannon, who's advising consumers to prepare for flu season by getting their shots and stocking up on the Swiss pharma's over-the-counter remedy, Theraflu.

Inovio, MedImmune and Penn unite to fight the flu on DARPA's dime

Inovio Pharmaceuticals, AstraZeneca's MedImmune and the University of Pennsylvania have joined forces to study influenza and antibiotic-resistant bacteria, drawing on $12.2 million in federal funds.

Sanofi bird flu vax prompts immune response in PhII--but only with Novartis adjuvant

As it works to refine its vaccine strategy for the event of an avian flu pandemic, the NIH is trialing Sanofi's H7N9 vaccine at a range of doses and with a variety of adjuvant combinations. And now, it has one that looks promising.

Pharmacies continue push to lower barriers to seasonal flu vaccination

In the years since the H1N1 pandemic, pharmacies have established themselves as major providers of vaccines, with Walgreens and CVS administering jabs to more than 10 million people last year. But while anything that makes it easier for patients to get vaccinated is welcomed by public health officials and manufacturers, physicians have reservations about pharmacies stepping onto their turf.

AstraZeneca sends James Van Der Beek 'camping' to promote FluMist Quadrivalent

To get the word out on AstraZeneca's needle-free FluMist Quadrivalent vaccine, the company has brought on James Van Der Beek--of "Dawson's Creek" fame--to participate in its "Insist on the Mist" campaign.